Trial Profile
Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 May 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Cisplatin; Cytarabine; Dexamethasone; Dexamethasone; Etoposide; Fotemustine; Melphalan; Pegfilgrastim; Pegfilgrastim; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms FIL-Veral12
- 17 Jun 2022 Primary endpoint (Complete Response (CR) Rate) has not been met according to results presented at the 27th Congress of the European Haematology Association.
- 17 Jun 2022 Final results of Phase II Randomized Fil-Veral12 presented at the 27th Congress of the European Haematology Association
- 21 Dec 2020 Status changed from active, no longer recruiting to completed.